Ara Partners Reaches Final Close for Inaugural Infrastructure Fund, Surpassing Target
BOSTON and DUBLIN, May 1, 2025 /PRNewswire/ -- Ara Partners, a global investment firm dedicated to the decarbonization of the industrial economy, today announced that it has raised over $800 million for its Ara Infrastructure strategy, including its debut Fund, Ara Infrastructure Fund I, and associated co-investment vehicles. The Fund exceeded its target of $500 million, drawing strong support from Ara's existing investor base and a diverse set of new institutional investors comprised of pension funds, insurance companies, sovereign wealth funds, endowments, and foundations from North America, Europe, and the Asia-Pacific region.
Ara Infrastructure is led by industry veterans George Yong and Teresa O'Flynn. The strategy targets mid-market infrastructure with a focus on developing new and re-purposing high quality legacy assets for the low carbon industrial economy. Since launching the strategy in 2022, Ara Infrastructure has completed three investments, with a fourth commitment expected shortly. The Fund now owns 12 operational assets across North America and Europe. Portfolio companies include:
'We are incredibly proud of this milestone and grateful for the robust support from our investors. This Fund enables us to pursue a generational investment opportunity across Europe and North America, characterized by increasing energy and industrial demand, a move towards decentralized energy systems, as well as the need to ensure an economic path toward a lower carbon economy,' said Teresa O'Flynn, Partner and Co-Head of Infrastructure at Ara Partners. 'We are focused on building high-value decarbonization assets that future-proof businesses for the modern economy and support the energy transition.''
'We are committed to delivering attractive risk-adjusted returns with classic infrastructure characteristics to our investors,' said George Yong, Partner and Co-Head of Infrastructure. 'Ara's builder capabilities and DNA ideally position us to navigate the disjointed, yet opportunity-rich, world of middle-market sustainable infrastructure. Companies in our target sectors seek more than just a capital provider; we believe our in-house operational capabilities make us a value-add partner of choice. We look forward to supporting exceptional teams and companies across these sectors.'
Rede Partners acted as placement agent and Debevoise & Plimpton LLP served as legal counsel in the formation of Ara Infrastructure Fund I.
About Ara Partners
Founded in 2017, Ara Partners is a global private equity and infrastructure firm dedicated to decarbonizing the industrial economy. Ara seeks to build, scale, and optimize companies with significant decarbonization impact across the industrial and manufacturing, chemicals and materials, energy efficiency and fuels, and food and agriculture sectors. The company operates from offices in Houston, Boston, Dublin and Washington, D.C.. As of December 31, 2024, Ara Partners had approximately $6.2 billion of assets under management.
For more information about Ara Partners, please visit www.arapartners.com.
Media Contacts:
Catherine MacDonald, Ara Partners
[email protected]
Zach Harris, Prosek Partners
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/ara-partners-reaches-final-close-for-inaugural-infrastructure-fund-surpassing-target-302443285.html
SOURCE Ara Partners
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24-07-2025
- Yahoo
TotalEnergies and CMA CGM launch JV for LNG bunkering in Rotterdam
TotalEnergies and CMA CGM have entered an agreement to form a logistics joint venture focused on liquefied natural gas (LNG) bunkering at the Port of Rotterdam in the Netherlands. This 50:50 JV aims to develop and operate a new 20,000m3 LNG bunker vessel in Rotterdam by the end of 2028. The joint venture will offer a range of logistics services to vessels operating in the Amsterdam-Rotterdam-Antwerp (ARA) region, including CMA CGM's fleet and other shipping operators These services will encompass reload access at Gate terminal facilities and LNG bunker delivery. The JV will leverage TotalEnergies' existing infrastructure in the ARA region, including the 18,600m3 LNG bunker vessel Gas Agility, to offer comprehensive logistics services. The partnership is set to create synergies by integrating the JV's future LNG bunker vessel with the Gas Agility, thereby increasing delivery flexibility and operational efficiency. CMA CGM Group chairman and CEO Rodolphe Saadé said: 'With this joint venture, CMA CGM and TotalEnergies are taking a new step to support the energy transition in shipping. 'For the first time, a shipping company and an energy provider will jointly operate an LNG bunkering vessel, based in the port of Rotterdam. It is a concrete way to scale up alternative fuels and accelerate the decarbonisation of global trade.' TotalEnergies will also supply CMA CGM with up to 360,000 tonnes (t) of LNG annually from 2028 until 2040, supporting CMA CGM's ambition to achieve Net Zero Carbon by 2050 and catering to its growing fleet of dual-fuel LNG-powered vessels, which are expected to reach 123 by 2029. TotalEnergies chairman and CEO Patrick Pouyanné said: 'We are proud to further contribute, alongside a partner like CMA CGM, to the development of an LNG bunkering supply chain in one of Europe's leading port hubs. LNG is today the most mature and immediately available solution to reduce the environmental footprint of maritime transport. 'This strategic partnership not only strengthens our position as a major player in LNG bunkering but also illustrates the shared commitment of two leading French companies to actively support the energy transition.' The establishment of the LNG bunkering joint venture is pending regulatory approvals. Additionally, CMA CGM had partnered with ABB in March to enhance maritime safety through a new parametric roll algorithm. This development, integrated with ABB Ability OCTOPUS Marine Advisory system, combines CMA CGM's theoretical framework with advanced forecasting and monitoring of vessel motion behaviour. "TotalEnergies and CMA CGM launch JV for LNG bunkering in Rotterdam" was originally created and published by Ship Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
24-07-2025
- Yahoo
Major pay move for 2.6 million 'hardworking' Aussies: 'Keep their heads above water'
The government is trying to protect the pay rights of roughly 2.6 million workers by introducing new legislation to parliament. The bill would safeguard penalty and overtime rates for those on certain award contracts. The legislation is being introduced on Thursday, and Labor will be seeking support from both the Coalition and the Greens to get it approved. Employment and workplace relations minister Amanda Rishworth said this measure is essential for "hardworking" people. 'If you rely on the modern award safety net and work weekends, public holidays, early mornings or late nights, you deserve to have your wages protected,' she said. RELATED Major update on $5,520 HECS cash boost for millions The top 10 highest salaries in Australia paying up to $700,000 Rare 5 cent coin worth 25,000 times its value due to 'double headed' detail 'Millions of hardworking Australians rely on penalty rates and overtime rates to keep their heads above water, which is why this bill is so critical." Labor went to the election promising to protect penalty and overtime rates after a push from the Australian Retailers Association (ARA) to change how these pay benefits could work. The ARA made an application to the Fair Work Commission (FWC) that included more than a dozen argued the current General Retail Industry Award 2020 (GRIA) was unnecessarily convoluted because there are 994 individual pay rates that spanned nearly 100 pages. So, it suggested award workers earning $53,670 and above could be exempted from benefits like overtime rates, evening and weekend penalty rates, and annual leave loading. It also wanted to reduce rest times between shifts from 12 hours to 10 hours, and allow workers to waive their meal breaks to finish their shifts early. In exchange, workers would be given an opt-in 25 per cent boost to their base rate. But the application copped a spray from Labor at the time. 'Labor's longstanding position is that workers' wages should not go backwards," the then workplace relations minister Murray Watt said in a counter submission to the FWC. 'If you give up your nights and weekends to keep Australia fed and clothed, you deserve your penalty rates." How would the legislation work and will it pass? The government is now going one step further by bringing in strengthened legislation for award worker pay. Under Labor's proposal, an award would not be allowed to be altered if it could be shown that just one worker would be worse off under an arrangement that involved a change in overtime or penalty rates. However, the government could find it difficult to get this legislation passed. The opposition said the FWC already has enough powers to look after all types of workers and ensure they have the best possible conditions. 'There is no threat to penalty rates,' shadow industrial relations and employment spokesman Tim Wilson said recently. 'What there is, is a political focus of the government that isn't focused towards improving the economic conditions to help small businesses grow, to enable them to go on and employ the next generation of workers, to give those first generation, those first jobs to young Australians so that they can be independent, and be able to get on with their economic futures.'
Associated Press
09-07-2025
- Associated Press
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts trial profile Enrollment in Part A of MIRACLE reaches seven subjects treated and one additional subject in screening 16 additional clinical sites in Europe and the US expected to begin recruitment by the end of August; building to an expected 30 plus sites for Part A of MIRACLE Anticipated data readout of Part A remains in 2H 2025 HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in the country of Georgia has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as 'Ara-C' and for which the combination of Annamycin and Ara-C is referred to as 'AnnAraC') for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). This Phase 3 'MIRACLE' trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East. Additionally, the Company expects the first patient to be treated in Georgia to occur by the end of August, if not sooner. 'Building upon our recently announced CTA approval in the European Union (EU) from the European Medicines Agency (EMA), RAMPA approval of the MIRACLE trial protocol represents another important milestone and bolsters our ongoing enrollment efforts,' said Walter Klemp, Chairman and CEO of Moleculin. 'We expect to add 16 additional sites in Europe and the US to MIRACLE by the end of August. This will build to more than 30 sites by year-end for Part A of the MIRACLE. Adding to this progress, our recruitment in Part A of MIRACLE has hit seven subjects treated and one in screening with just our first site in Ukraine. All of this, importantly, supports our goal to report initial data on the first 45 subjects from Part A in the second half of 2025.' Mr. Klemp continued, 'This early success in recruitment underscores the capability of our clinical sites, with the first ten screened subjects within just three months of site activation, and it showcases the commitment of ARENSIA Exploratory Medicine's research clinic in Kyiv, Ukraine (ARENSIA). We are grateful for the continued international regulatory collaboration for this trial and believe it reflects the potential demand for Annamycin and the significant unmet need for better treatment options for R/R AML patients, especially venetoclax regimen failures where the outcomes from currently available therapies are considered dismal. Our team remains focused on driving enrollment and advancing this important program forward.' The MIRACLE study is a Phase 2B/3 clinical trial whereby data from the 2B portion will be combined with the Phase 3 portion for purposes of measuring its primary efficacy endpoint. MIRACLE is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents, utilizes an adaptive design whereby the first 75 to 90 subjects will be randomized (1:1:1) in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin, which Annamycin doses were specifically recommended by the FDA in the Company's end of Phase 1B/2 meeting. The protocol for the MIRACLE trial allows for the unblinding of preliminary primary efficacy data (Complete Remission or CR) and safety/tolerability of the three arms at 45 subjects, in addition to the conclusion of Part A (at 75 to 90 subjects). The first early unblinding will yield 30 subjects treated with Annamycin (190mg/m2 and 230 mg/m2) in combination with HiDAC and 15 subjects treated with just HiDAC plus placebo. The Company expects to reach the first unblinding (45 subjects) in the second half of 2025, in addition to the second unblinding, which is expected in the first half of 2026. This accelerated estimated timeline is due in part to the positive response the Company received in meetings during December with potential investigators regarding recruitment for the trial. As previously announced with regard to the EU, the clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study. Results will be submitted as a substantial modification to the existing approved CTA. For Part B of the trial, approximately 220 additional subjects will be randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin (randomized 1:1). The selection of the optimum dose will be based on the overall balance of safety, pharmacokinetics and efficacy, consistent with the FDA's new Project Optimus initiative. Patient dosing has commenced, and the initial data readout is on track for the second half of 2025. For more information about the MIRACLE trial, visit and reference identifier NCT06788756. Additionally, the clinical trial in the EU is on and the reference identifier there is 2024-518359-47-00. Annamycin, also known by its non-proprietary name of naxtarubicin, currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the EMA. About ARENSIA Exploratory Medicine GmbH ARENSIA Exploratory Medicine GmbH is a German operator of proprietary hospital-based research clinics, dedicated to performing complex clinical trials with novel molecules, involving patients across numerous disease areas. ARENSIA aims to speed up patients' access to innovative therapies by collaborating with cutting-edge pharmaceutical companies and currently operates 13 state-of-the-art research clinics across the United States of America and Eastern Europe. For more information about ARENSIA and its clinical operations, please visit About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the release of the initial data on the first 45 subjects in the trial and the Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 [email protected]
